Jump to content

ASR-2001

Add links
From Wikipedia, the free encyclopedia

ASR-2001
Clinical data
Other namesASR2001; 2CB-5PrO; 5-PrO-2C-B; 4-Bromo-2-methoxy-5-propoxyphenethylamine
Routes of
administration		Oral[1]
Drug classNon-hallucinogenic serotonin 5-HT2A receptor and 5-HT1B receptor agonist
ATC code
  • None
Pharmacokinetic data
Onset of action1–1.5 hours[1]
Duration of action8–10 hours[1]
Identifiers
  • 2-(4-bromo-2-methoxy-5-propoxyphenyl)ethanamine
PubChem CID
Chemical and physical data
FormulaC12H18BrNO2
Molar mass288.185 g·mol−1
3D model (JSmol)
  • CCCOC1=C(C=C(C(=C1)CCN)OC)Br
  • InChI=1S/C12H18BrNO2/c1-3-6-16-12-7-9(4-5-14)11(15-2)8-10(12)13/h7-8H,3-6,14H2,1-2H3
  • Key:SMMQLGYZANIEMB-UHFFFAOYSA-N

ASR-2001, also known as 2CB-5PrO or as 4-bromo-2-methoxy-5-propoxyphenethylamine, is a non-hallucinogenic serotonin receptor agonist agonist of the phenethylamine, 2C, and TWEETIO families which is under development for the treatment of psychiatric disorders.[2][3][4][5][6][7] It is the TWEETIO analogue of 2C-B in which the 5-methoxy group is replaced with a 5-propoxy group.[5][8]

The drug is a non-hallucinogenic serotonin 5-HT2A receptor agonist and is orally active, highly potent, and has high selectivity over the serotonin 5-HT2B receptor (94-fold in terms of activational potency).[3][4][5][1][8] It is also a highly potent agonist of the serotonin 5-HT1B receptor, whereas its activity at the serotonin serotonin 5-HT1A receptor was very weak and its activity at the 5-HT2C receptor was not described.[8] ASR-2001 showed no significant activity at a variety of other sites, including other serotonin receptors and the monoamine transporters.[8]

According to its developers, ASR-2001 has no overt psychedelic effects, but produces a "focusing-type" "state of mental clarity" without the frank psychostimulant effects of drugs like amphetamine and methylphenidate.[3][4][1] It is said to not disturb but to potentially facilitate detailed work.[1] The drug is said to have a dose range of 10 to 40 mg, an onset of 1 to 1.5 hours, and a duration of 8 to 10 hours.[1] Its effects are described as "subtle".[1]

ASR-2001 is under development by Nick Cozzi and Paul F. Daley and colleagues at the Alexander Shulgin Research Institute (ASRI).[3][4][1][2] It was first described in 2023[1][3] and was patented in 2024.[5][8] As of early 2025, ASR-2001 is in the preclinical research stage of development.[7][2]

See also

[edit]

References

[edit]
  1. ^ a b c d e f g h i j Goldstein L (10 July 2023). "Pioneering Psychedelics Scientist Alexander "Sasha" Shulgin's Legacy Lives On Via New Compounds And Research". Benzinga. Retrieved 19 April 2025.
  2. ^ a b c "Delving into the Latest Updates on ASR-2001 with Synapse". Synapse. 5 April 2025. Retrieved 19 April 2025.
  3. ^ a b c d e Busby M (2 November 2023). "The Heirs to a Vault of Novel Psychedelics Take a Trip Into the Unknown". DoubleBlind Mag. Retrieved 19 April 2025.
  4. ^ a b c d Busby M (30 March 2025). "What Happens When You Inherit 500 Psychedelic Compounds?". DoubleBlind Mag. Retrieved 19 April 2025.
  5. ^ a b c d Kargbo RB (April 2025). "Innovative Approaches in Psychedelics, AI, and Communication: A Multi-Domain Perspective". ACS Med Chem Lett. 16 (4): 514–516. doi:10.1021/acsmedchemlett.5c00114. PMID 40236531.
  6. ^ "Alexander Shulgin Research Institute discovers new phenylalkylamine compounds". BioWorld. 19 December 2024. Retrieved 19 April 2025.
  7. ^ a b Michael Haichin (2024). "Psychedelics Drug Development Tracker". Psychedelic Alpha. Retrieved 29 January 2025.
  8. ^ a b c d e WO patent 2024243599A1, Mark J. Martini; Nicholas V. Cozzi & Paul F. Daley et al., "Asymmetric phenylalkylamines", published 28 November 2024, assigned to Alexander Shulgin Research Institute 
[edit]


Stub icon

This psychoactive drug-related article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=ASR-2001&oldid=1286433136"